Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- Glutamate Reducing Interventions in Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Glutamate Reducing Interventions in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03321617).
- GLUTAMICSIndependent statistical analysis of Glutamate for Metabolic Intervention in Coronary Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00489827).
- Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy: Complete Statistical AnalysisIndependent statistical analysis of Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer: Complete Statistical AnalysisIndependent statistical analysis of Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01048905).
- Glutathione and Function in HIV Patients: Complete Statistical AnalysisIndependent statistical analysis of Glutathione and Function in HIV Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02348775).
- Glutathione Metabolism in Adolescents With Type 1 Diabetes – Study A: Complete Statistical AnalysisIndependent statistical analysis of Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Glycemia in Diabetic Elders Trial: Complete Statistical AnalysisIndependent statistical analysis of Glycemia in Diabetic Elders Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02029846).
- Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery: Complete Statistical AnalysisIndependent statistical analysis of Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00328094).
- Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy: Complete Statistical AnalysisIndependent statistical analysis of Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: Complete Statistical AnalysisIndependent statistical analysis of Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment: primary endpoint results, effect estimate with confidence interval, sample-size…
- Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD: Complete Statistical AnalysisIndependent statistical analysis of Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD: primary endpoint results, effect estimate with confidence interval,…
- GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- GMRTIndependent statistical analysis of Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01726036).
- GMRx2_PCTIndependent statistical analysis of Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GMTIndependent statistical analysis of Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02486263).
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC: Complete Statistical AnalysisIndependent statistical analysis of GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GO-COLITISIndependent statistical analysis of Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02092285).
- GO-VIVAIndependent statistical analysis of A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: primary endpoint results,…
- GO2 PEEPIndependent statistical analysis of Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GOALIndependent statistical analysis of Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GOALSIndependent statistical analysis of Gaining Optimism After Weight Loss Surgery (GOALS) II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04868032).
- Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease: Complete Statistical AnalysisIndependent statistical analysis of Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GOCIndependent statistical analysis of Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GOLDEN-3Independent statistical analysis of Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): Complete Statistical AnalysisIndependent statistical analysis of Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GOLMePsAIndependent statistical analysis of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04108468).
- GonoScreenIndependent statistical analysis of GonoScreen: Efficacy of Screening STIs in MSM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04269434).
- GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry: Complete Statistical AnalysisIndependent statistical analysis of GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02266342).
- GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03): Complete Statistical AnalysisIndependent statistical analysis of GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04706273).
- Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00540722).
- Gout in the ED and Improving Research Participation: Complete Statistical AnalysisIndependent statistical analysis of Gout in the ED and Improving Research Participation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04075903).
- Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers: Complete Statistical AnalysisIndependent statistical analysis of Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GPSIndependent statistical analysis of Gelatines in Pediatric PatientS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02495285).
- GQ01Independent statistical analysis of The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults: Complete Statistical AnalysisIndependent statistical analysis of GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GRABM-LIndependent statistical analysis of GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GRACEIndependent statistical analysis of GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03769844).
- GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.: Complete Statistical AnalysisIndependent statistical analysis of GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV)…
- GRAMSIndependent statistical analysis of Gadobutrol Enhanced MRA of the Renal Arteries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01344460).
- GRAND-307Independent statistical analysis of Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes: primary endpoint results, effect estimate with…
- Granulox01Independent statistical analysis of A Multicentre European Study to Evaluate Granulox® Used in the Treatment Pathway of Predominantly Chronic Venous Leg Ulcers (VLUs).: primary endpoint results, effect estimate with confidence interval, sample-size…
- GRAPEIndependent statistical analysis of Group B Streptococcus Response After Probiotic Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04721912).
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GRAVITYIndependent statistical analysis of 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GRAY-BIndependent statistical analysis of GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): primary endpoint results, effect estimate with confidence interval, sample-size planning…